Review article: Addressing risk factors in chronic kidney disease mineral and bone disorder: Can we influence patient-level outcomes?

Nephrology

Volumn 14, Issue 4, 2009, Pages 416-427

  O'Shea, Stacey ^a   Johnson, David W ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

Bone mineral metabolism; Calcimimetic; Hyperparathyroidism; Mortality; Phosphate; Vitamin D

Indexed keywords

22 OXACALCITRIOL; ALUMINUM; ALUMINUM HYDROXIDE; CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; CALCIUM KETOGLUTARATE; CARBONIC ACID DERIVATIVE; CINACALCET; CITRATE CALCIUM; DOXERCALCIFEROL; FALECALCITRIOL; LANTHANUM; LATHANUM CARBONIC ACID; MAGNESIUM; MAGNESIUM CARBONATE; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE BINDING AGENT; PLACEBO; SEVELAMER; UNCLASSIFIED DRUG; VITAMIN D;

ANEMIA; ARTERY CALCIFICATION; BONE DISEASE; BONE MINERAL; BONE MINERALIZATION; BONE TOXICITY; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; DEMENTIA; DIALYSATE; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCALCEMIA; HYPERMAGNESEMIA; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; METABOLIC BONE DISEASE; MYOPATHY; NAUSEA; NONHUMAN; PARATHYROIDECTOMY; PERIPHERAL EDEMA; PHOSPHATE BLOOD LEVEL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN DIET; PROTEIN RESTRICTION; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; TREATMENT OUTCOME;

HUMANS; HYPERPARATHYROIDISM, SECONDARY; RENAL INSUFFICIENCY, CHRONIC; RENAL OSTEODYSTROPHY; RISK FACTORS; TREATMENT OUTCOME;

EID: 67650745577     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2009.01114.x     Document Type: Review

References (90)

1. Coen G, Ballanti P, Bonucci E et al. Renal osteodystrophy in predialysis and hemodialysis patients: Comparison of histologic patterns and diagnostic predictivity of intact PTH. Nephron 2002 91 : 103 11.
2. Ogata H, Koiwa F, Kinugasa E, Akizawa T. CKD-MBD: Impact on management of kidney disease. Clin. Exp. Nephrol. 2007 11 : 261 8.
3. Ogata H, Koiwa F, Ito H, Kinugasa E. Therapeutic strategies for secondary hyperparathyroidism in dialysis patients. Ther. Apher. Dial. 2006 10 : 355 63.
4. Fukagawa M, Akizawa T. Calcium abnormalities of dialysis patients. J. Bone Miner. Metab. 2006 24 : 160.
5. Cunningham J. Management of secondary hyperparathyroidism. Ther. Apher. Dial. 2005 9 (Suppl 1 S35 40.
6. Piraino B, Chen T, Cooperstein L, Segre G, Puschett J. Fractures and vertebral bone mineral density in patients with renal osteodystrophy. Clin. Nephrol. 1988 30 : 57 62. (Pubitemid 18193295)
7. Alem AM, Sherrard DJ, Gillen DL et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int. 2000 58 : 396 9.
8. Goldsmith DJ, Covic A, Sambrook PA, Ackrill P. Vascular calcification in long-term haemodialysis patients in a single unit: A retrospective analysis. Nephron 1997 77 : 37 43. (Pubitemid 27395339)
9. Lazaro RP, Kirshner HS. Proximal muscle weakness in uremia. Case reports and review of the literature. Arch. Neurol. 1980 37 : 555 8.
10. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J. Am. Soc. Nephrol. 2004 15 : 2208 18.
11. Joy MS, Karagiannis PC, Peyerl FW. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. J. Manag. Care Pharm. 2007 13 : 397 411. (Pubitemid 47162414)
12. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J. Am. Soc. Nephrol. 2001 12 : 2131 8.
13. Danese MD, Belozeroff V, Smirnakis K, Rothman KJ. Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin. J. Am. Soc. Nephrol. 2008 3 : 1423 9.
14. Moe S, Drueke T, Cunningham J et al. Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006 69 : 1945 53.
15. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis. 2003 42 : S1 201.
16. Elder G, Faull R, Branley P, Hawley C. The CARI guidelines. Management of bone disease, calcium, phosphate and parathyroid hormone. Nephrology (Carlton) 2006 11 (Suppl 1 S230 61.
17. Emmett M, Sirmon MD, Kirkpatrick WG, Nolan CR, Schmitt GW, Cleveland MB. Calcium acetate control of serum phosphorus in hemodialysis patients. Am. J. Kidney Dis. 1991 17 : 544 50.
18. Bro S, Rasmussen RA, Handberg J, Olgaard K, Feldt-Rasmussen B. Randomized crossover study comparing the phosphate-binding efficacy of calcium ketoglutarate versus calcium carbonate in patients on chronic hemodialysis. Am. J. Kidney Dis. 1998 31 : 257 62.
19. Lerner A, Kramer M, Goldstein S, Caruana R, Epstein S, Raja R. Calcium carbonate. A better phosphate binder than aluminum hydroxide. ASAIO Trans. 1986 32 : 315 18.
20. Janssen MJ, van der KA, ter Wee PM, van Boven WP. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients. Clin. Nephrol. 1996 45 : 111 19.
21. Pflanz S, Henderson IS, McElduff N, Jones MC. Calcium acetate versus calcium carbonate as phosphate-binding agents in chronic haemodialysis. Nephrol. Dial. Transplant. 1994 9 : 1121 4.
22. Ring T. Calcium acetate versus calcium carbonate as phosphate binders. Nephron 1993 63 : 119. (Pubitemid 23008175)
23. Caravaca F, Fernandez MA, Ruiz-Calero R et al. Effects of oral phosphorus supplementation on mineral metabolism of renal transplant recipients. Nephrol. Dial. Transplant. 1998 13 : 2605 11.
24. Delmez JA, Kelber J, Norword KY, Giles KS, Slatopolsky E. Magnesium carbonate as a phosphorus binder: A prospective, controlled, crossover study. Kidney Int. 1996 49 : 163 7.
25. Ittel TH, Schafer C, Schmitt H, Gladziwa U, Sieberth HG. Calcium carbonate as a phosphate binder in dialysis patients: Evaluation of an enteric-coated preparation and effect of additional aluminium hydroxide on hyperaluminaemia. Klin. Wochenschr. 1991 69 : 59 67.
26. Jespersen B, Jensen JD, Nielsen HK et al. Comparison of calcium carbonate and aluminium hydroxide as phosphate binders on biochemical bone markers, PTH(1-84), and bone mineral content in dialysis patients. Nephrol. Dial. Transplant. 1991 6 : 98 104.
27. Caravaca F, Santos I, Cubero JJ et al. Calcium acetate versus calcium carbonate as phosphate binders in hemodialysis patients. Nephron 1992 60 : 423 7.
28. d'Almeida Filho EJ, da Cruz EA, Hoette M, Ruzany F, Keen LN, Lugon JR. Calcium acetate versus calcium carbonate in the control of hyperphosphatemia in hemodialysis patients. Sao Paulo Med. J. 2000 118 : 179 84.
29. Almirall J, Veciana L, Llibre J. Calcium acetate versus calcium carbonate for the control of serum phosphorus in hemodialysis patients. Am. J. Nephrol. 1994 14 : 192 6.
30. Birck R, Zimmermann E, Wassmer S, Nowack R, van der Woude FJ. Calcium ketoglutarate versus calcium acetate for treatment of hyperphosphataemia in patients on maintenance haemodialysis: A cross-over study. Nephrol. Dial. Transplant. 1999 14 : 1475 9.
31. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007 71 : 438 41.
32. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002 62 : 245 52.
33. Block GA, Spiegel DM, Ehrlich J et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005 68 : 1815 24.
34. Bleyer AJ, Burke SK, Dillon M et al. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am. J. Kidney Dis. 1999 33 : 694 701. (Pubitemid 29159935)
35. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N. Engl. J. Med. 2000 342 : 1478 83.
36. Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol. Dial. Transplant. 2000 15 : 1014 21.
37. Asmus HG, Braun J, Krause R et al. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrol. Dial. Transplant. 2005 20 : 1653 61.
38. Chertow GM, Dillon M, Burke SK et al. A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clin. Nephrol. 1999 51 : 18 26.
39. Qunibi WY, Hootkins RE, McDowell LL et al. Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int. 2004 65 : 1914 26.
40. Hervas JG, Prados D, Cerezo S. Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: A comparison with calcium acetate. Kidney Int. Suppl 2003 S69 72.
41. Koiwa F, Onoda N, Kato H et al. Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan. Ther. Apher. Dial. 2005 9 : 340 6.
42. Shaheen FA, Akeel NM, Badawi LS, Souqiyyeh MZ. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients. Saudi Med. J. 2004 25 : 785 91.
43. Block G, Spiegel DM, Ehrlich J et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005 68 : 1815 24.
44. Silver J. The details bedevil DCOR. Kidney Int. 2007 72 : 1041 3.
45. Suki WN, Zabaneh R, Cangiano JL et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007 72 : 1130 7.
46. Alfrey AC, LeGendre GR, Kaehny WD. The dialysis encephalopathy syndrome. Possible aluminum intoxication. N. Engl. J. Med. 1976 294 : 184 8.
47. Wills MR, Savory J. Aluminium poisoning: Dialysis encephalopathy, osteomalacia, and anaemia. Lancet 1983 2 : 29 34.
48. Andreoli SP, Bergstein JM, Sherrard DJ. Aluminum intoxication from aluminum-containing phosphate binders in children with azotemia not undergoing dialysis. N. Engl. J. Med. 1984 310 : 1079 84.
49. Katopodis KP, Andrikos EK, Gouva CD et al. Sevelamer hydrochloride versus aluminum hydroxide: Effect on serum phosphorus and lipids in CAPD patients. Perit. Dial. Int. 2006 26 : 320 7.
50. Hutchison AJ, Speake M, Al Baaj F. Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: A 4-week, dose-finding, open-label study with lanthanum carbonate. Nephrol. Dial. Transplant. 2004 19 : 1902 6.
51. Hutchison AJ, Maes B, Vanwalleghem J et al. Long-term efficacy and tolerability of lanthanum carbonate: Results from a 3-year study. Nephron. Clin. Pract. 2006 102 : c61 71
52. Hutchison AJ, Maes B, Vanwalleghem J et al. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: A 6-month, randomized, comparative trial versus calcium carbonate. Nephron. Clin. Pract. 2005 100 : c8 19.
53. Joy MS, Finn WF. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: A new phosphate binder for the treatment of hyperphosphatemia. Am. J. Kidney Dis. 2003 42 : 96 107. (Pubitemid 36807658)
54. Finn WF, Joy MS. A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis. Curr. Med. Res. Opin. 2005 21 : 657 64.
55. Shigematsu T. Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis. Ther. Apher. Dial. 2008 12 : 55 61. (Pubitemid 351197453)
56. Al Baaj F, Speake M, Hutchison AJ. Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study. Nephrol. Dial. Transplant. 2005 20 : 775 82.
57. D'Haese PC, Spasovski GB, Sikole A et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int. Suppl. 2003 85 : S73 78.
58. Malluche HH, Siami GA, Swanepoel C et al. Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years. Clin. Nephrol. 2008 70 : 284 95.
59. Lacour B, Lucas A, Auchere D, Ruellan N, Serre Patey NM, Drueke TB. Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int. 2005 67 : 1062 9.
60. McLeod C, Cox A, Bramall N. The need for contamination control in studies on lanthanum biodisposition. Kidney Int. 2005 68 : 2906 7.
61. Tzanakis IP, Papadaki AN, Wei M et al. Magnesium carbonate for phosphate control in patients on hemodialysis. A randomized controlled trial. Int. Urol. Nephrol. 2008 40 : 193 201.
62. Spiegel DM, Farmer B, Smits G, Chonchol M. Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: A pilot study. J. Ren. Nutr. 2007 17 : 416 22.
63. Pitts TO, Piraino BH, Mitro R et al. Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J. Clin. Endocrinol. Metab. 1988 67 : 876 81.
64. Silver J, Naveh-Many T, Mayer H, Schmelzer HJ, Popovtzer MM. Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J. Clin. Invest. 1986 78 : 1296 301.
65. Palmer SC, McGregor DO, Macaskill P, Craig JC, Elder GJ, Strippoli GF. Meta-analysis: Vitamin D compounds in chronic kidney disease. Ann. Intern. Med. 2007 147 : 840 53.
66. Tonelli M. Vitamin D in patients with chronic kidney disease: Nothing new under the sun. Ann. Intern. Med. 2007 147 : 880 1.
67. Olgaard K, Lewin E. Use (or misuse) of vitamin D treatment in CKD and dialysis patients: A recent meta-analysis on vitamin D compounds in chronic kidney disease ]1[ and an editorial comment ]2[ accompanying this meta-analysis have already been published. We believe that these papers deserve some comments in the interest of the NDT readership. Nephrol. Dial. Transplant. 2008 23 : 1786 9.
68. Block GA, Martin KJ, de Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N. Engl. J. Med. 2004 350 : 1516 25.
69. Lindberg JS, Moe SM, Goodman WG et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int. 2003 63 : 248 54.
70. Fukagawa M, Yumita S, Akizawa T et al. Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol. Dial. Transplant. 2008 23 : 328 35.
71. Malluche HH, Monier-Faugere MC, Wang G et al. An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clin. Nephrol. 2008 69 : 269 78.
72. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. 2005 68 : 1793 800.
73. Strippoli GF, Palmer S, Tong A, Elder G, Messa P, Craig JC. Meta-analysis of biochemical and patient-level effects of calcimimetic therapy. Am. J. Kidney Dis. 2006 47 : 715 26.
74. Strippoli GF, Tong A, Palmer SC, Elder G, Craig JC. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. Cochrane Database Syst. Rev. 2006 4 : CD006254.
75. Chertow GM, Pupim LB, Block GA et al. Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview. Clin. J. Am. Soc. Nephrol. 2007 2 : 898 905.
76. Yajima A, Inaba M, Tominaga Y, Ito A. Bone formation by minimodeling is more active than remodeling after parathyroidectomy. Kidney Int. 2008 74 : 775 81.
77. Pasch A. Bone mass gain after parathyroidectomy. Kidney Int. 2008 74 : 697 9.
78. Wang HY, Yu CC, Huang CC. Successful treatment of severe calciphylaxis in a hemodialysis patient using low-calcium dialysate and medical parathyroidectomy: Case report and literature review. Ren. Fail. 2004 26 : 77 82.
79. Toussaint N, Cooney P, Kerr PG. Review of dialysate calcium concentration in hemodialysis. Hemodial. Int. 2006 10 : 326 37.
80. Di Iorio BR, Minutolo R, De Nicola L et al. Supplemented very low protein diet ameliorates responsiveness to erythropoietin in chronic renal failure. Kidney Int. 2003 64 : 1822 8.
81. Van Eps CL, Jeffries JK, Anderson JA et al. Mineral metabolism, bone histomorphometry and vascular calcification in alternate night nocturnal haemodialysis. Nephrology (Carlton) 2007 12 : 224 33.
82. Mucsi I, Hercz G, Uldall R, Ouwendyk M, Francoeur R, Pierratos A. Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int. 1998 53 : 1399 404.
83. Al Hejaili F, Kortas C, Leitch R et al. Nocturnal but not short hours quotidian hemodialysis requires an elevated dialysate calcium concentration. J. Am. Soc. Nephrol. 2003 14 : 2322 8.
84. Lindsay RM, Alhejaili F, Nesrallah G et al. Calcium and phosphate balance with quotidian hemodialysis. Am. J. Kidney Dis. 2003 42 : 24 9.
85. Strippoli GF, Tognoni G, Navaneethan SD, Nicolucci A, Craig JC. Haemoglobin targets: We were wrong, time to move on. Lancet 2007 369 : 346 50.
86. Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 2005 353 : 238 48.
87. Eknoyan G, Beck GJ, Cheung AK et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N. Engl. J. Med. 2002 347 : 2010 19.
88. Paniagua R, Amato D, Vonesh E et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J. Am. Soc. Nephrol. 2002 13 : 1307 20.
89. Block G, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007 71 : 438 41.
90. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001 38 : 938 42.